Recent studies have demonstrated an important role of PTEN expression in controlling tumor immune microenvironment (TIME) and its contribution to immunomodulatory therapy resistance in patients with glioma [51,52,53,54,55]. The gene discussed is PTEN; the disease is neoplasm.